共 50 条
Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders
被引:0
作者:
David A. Smelson
Lisa Dixon
Thomas Craig
Stephen Remolina
Steven L. Batki
Noosha Niv
Richard Owen
机构:
[1] Edith Nourse Rogers VA Hospital,Department of Veterans Affairs
[2] University of Massachusetts Medical School,Department of Psychiatry
[3] Department of Veterans Affairs VISN 4 MIRECC,Department of Veterans Affairs
[4] University of Maryland,Center for Mental Healthcare & Outcomes Research
[5] American Psychiatric Association,undefined
[6] New Jersey Health Care System,undefined
[7] University of California,undefined
[8] San Francisco VA Medical Center,undefined
[9] SUNY Upstate Medical University,undefined
[10] University of California,undefined
[11] Central Arkansas Veterans Health Care System,undefined
来源:
CNS Drugs
|
2008年
/
22卷
关键词:
Schizophrenia;
Clozapine;
Risperidone;
Olanzapine;
Naltrexone;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Substance abuse among individuals with schizophrenia is common and is often associated with poor clinical outcomes. Comprehensive, integrated pharmacological and psychosocial treatments have been shown to improve these outcomes. While a growing number of studies suggest that second-generation antipsychotic medications may have beneficial effects on the treatment of co-occurring sub-stance use disorders, this review suggests that the literature is still in its infancy. Few existing well controlled trials support greater efficacy of second-generation antipsychotics compared with first-generation antipsychotics or any particular second-generation antipsychotic. This article focuses on and reviews studies involving US FDA-approved medications for co-occurring substance abuse problems among individuals with schizophrenia.
引用
收藏
页码:903 / 916
页数:13
相关论文
共 50 条